# Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects

> **NCT00464802** · PHASE1 · COMPLETED · sponsor: **Bausch Health Americas, Inc.** · enrollment: 36 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MOA-728

## Key facts

- **NCT ID:** NCT00464802
- **Lead sponsor:** Bausch Health Americas, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2019-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00464802

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00464802, "Study Evaluating the Safety and Tolerability of a New Intravenous Formulation of MOA-728 in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00464802. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*